Summary

The market for transplant diagnostics is valued at around USD 5.61 billion in 2026 and is expected to reach USD 8.14 billion by 2031, at a growth rate of 7.8%. The growing number of organ transplantation procedures is driving the demand for various testing methods, including donor-recipient compatibility testing, histocompatibility testing, infectious disease testing, and blood profiling. Additionally, the rising adoption of molecular diagnostic technologies, such as PCR (polymerase chain reaction) and NGS (next-generation sequencing), is further fueling market growth. These technologies offer advantages such as high procedural efficacy, quick turnaround times, and real-time sample analysis. Furthermore, increasing awareness of the benefits of molecular diagnostic techniques in reducing the risk of graft rejection and improving transplantation outcomes is also contributing to market expansion. “The diagnostic applications segment is expected to witness the fastest growth rate in the transplant diagnostics market, by application, during the forecast period.” Based on application, the transplant diagnostics market is divided into diagnostic applications and research applications. In 2025, the diagnostic applications segment is expected to experience the fastest growth in the transplant diagnostics market. This growth is primarily due to advancements in molecular assay techniques and the increasing use of these procedures for pathogen detection and histocompatibility testing. Additionally, the rising incidence of chronic diseases that require transplantation is boosting demand for transplant diagnostic products and services. There is also a greater risk of genetic disorders and pathogen infections following transplantation, which supports the need for effective donor-recipient compatibility testing and post-transplant monitoring. Furthermore, growing awareness of the importance of accurate transplant diagnostics in reducing the risks of graft rejection and improving transplantation outcomes is contributing to the expansion of this segment. “The solid organ transplantation segment accounted for the largest market share in the transplant diagnostics market, by type, in 2025.” Based on transplant type, the transplant diagnostics market is divided into solid organ transplantation, stem cell transplantation, soft tissue transplantation, and bone marrow transplantation. In 2025, the solid organ transplantation segment led the transplant diagnostics market. This segment's significant share is mainly due to the growing use of transplant diagnostic products for various purposes, including donor-recipient compatibility testing, infectious disease testing, histocompatibility testing, genomic profiling, and blood profiling during solid organ transplantation procedures. Moreover, the increasing number of organ transplantation procedures, supportive government regulations, the rising prevalence of chronic diseases and disorders requiring transplantation, and technological advancements in transplant diagnostics are further contributing to the growth of this segment. “The Asia Pacific is the fastest-growing market for transplant diagnostics during the forecast period.” Based on region, the transplant diagnostics market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, the Asia Pacific region is expected to see the fastest growth in the transplant diagnostics market. This growth is primarily driven by increased healthcare spending, rapid advances in healthcare infrastructure, greater adoption of advanced diagnostic technologies, and significant economic growth in emerging Asia-Pacific countries. Additionally, factors such as a rising elderly population, an increased prevalence of chronic diseases requiring transplants, and growing government initiatives to modernize healthcare systems in countries like China, India, and Japan are further supporting market expansion. Furthermore, Japan's provision of universal healthcare coverage for transplantation-related procedures and the burgeoning medical tourism industry across Asia Pacific countries are also contributing to the growth of the transplant diagnostics market in the region. The breakup of the profile of primary participants in the transplant diagnostics market: ・ By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) ・ By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%) ・ By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) The key players in the molecular infectious disease testing market are Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMérieux (France), Becton, Dickinson and Company (US), Illumina, Inc. (US), DiaSorin S.p.A. (Italy), CAREDX, INC. (US), Werfen (Spain), Hologic, Inc. (US), Merck KGaA (Germany), Eurobio Scientific (France), Biofortuna Limited (UK), BAG Diagnostics GmbH (Germany), Fujirebio (Japan), HistoGenetics LLC (US), PacBio (US), TBG Biotechnology Corp (Taiwan), Scisco Genetics, Inc. (US), inno-train Diagnostik GmbH (Germany), Bionobis (France), Takara Bio Inc. (Japan), Krishgen Biosystems Private Limited (India), and Prolmmune Ltd. (UK). Research Coverage: This research report categorizes the transplant diagnostics market by product & service (reagents & consumables, instruments, and software & services), technology {molecular assays [PCR-based molecular assays (real-time PCR, sequence-specific primer-PCR, sequence-specific oligonucleotide-PCR, and other PCR-based molecular assays), sequencing-based molecular assays (Sanger sequencing, next-generation sequencing, and other sequencing-based molecular assays)] and non-molecular assays}, application {diagnostic applications [pre-transplantation diagnostics (infectious disease testing, histocompatibility testing, and blood profiling) and post-transplantation diagnostics] and research applications}, transplant type [solid organ transplantation (kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, and other organ transplantation), stem cell transplantation, soft tissue transplantation, and bone marrow transplantation], end user (hospitals & transplant centers, research & academic institutes, and independent reference laboratories), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). This report provides a comprehensive overview of the key factors driving growth in the transplant diagnostics market, including drivers, restraints, opportunities, and challenges. It offers an in-depth analysis of the major industry players, highlighting their business models, available solutions, key strategies, recent acquisitions, and agreements. Additionally, the report includes a competitive analysis of emerging startups in the transplant diagnostics market. Reasons to Buy this Report: The report will assist market leaders and new entrants in the transplant diagnostics industry by providing estimated revenue figures for the overall market and its subsegments. It aims to help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: ・ Analysis of key drivers (increasing number of transplant procedures, advancements in molecular diagnostic technologies, increasing public-private funding for transplant research, and rising prevalence of infectious diseases), restraints (high cost of advanced molecular diagnostic techniques and limited access to advanced transplant diagnostic infrastructure in emerging economies), opportunities (increasing adoption of cross-matching and chimerism testing and growing awareness regarding organ donation and transplantation), and challenges (gap between organ donor availability and transplant demand) influencing the growth of the transplant diagnostics market. ・ Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the transplant diagnostics market. ・ Market Development: Comprehensive information about lucrative markets; the report analyzes the transplant diagnostics market across varied regions. ・ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the transplant diagnostics market. ・ Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), and bioMérieux (France).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 MARKETS COVERED & REGIONAL SCOPE 42
1.3.2 INCLUSIONS & EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.4 CURRENCY CONSIDERED 44
1.5 STAKEHOLDERS 44
1.6 SUMMARY OF CHANGES 45
2 EXECUTIVE SUMMARY 46
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 46
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 47
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 48
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 49
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 50
3 PREMIUM INSIGHTS 51
3.1 TRANSPLANT DIAGNOSTICS MARKET OVERVIEW 51
3.2 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 52
3.3 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 52
3.4 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2026 VS. 2031 53
3.5 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2026 VS. 2031 53
3.6 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 54
3.7 TRANSPLANT DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 56
4.2.1 DRIVERS 56
4.2.1.1 Increasing number of transplant procedures 56
4.2.1.2 Advancements in molecular diagnostic technologies 57
4.2.1.3 Increasing public-private funding for transplant research 58
4.2.1.4 Rising incidence of chronic diseases 59
4.2.2 RESTRAINTS 59
4.2.2.1 High cost of instruments and consumables 59
4.2.2.2 Limited access to advanced transplant diagnostic infrastructure in emerging economies 60
4.2.3 OPPORTUNITIES 61
4.2.3.1 Increasing adoption of cross-matching and chimerism testing 61
4.2.3.2 Growing awareness regarding organ donation and transplantation 61
4.2.4 CHALLENGES 62
4.2.4.1 Gap between organ donor availability and transplant demand 62
4.3 UNMET NEEDS & WHITE SPACES 63
4.3.1 UNMET NEEDS IN TRANSPLANT DIAGNOSTICS MARKET 63
4.3.2 WHITE SPACE OPPORTUNITIES 64
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65
4.4.1 INTERCONNECTED MARKETS 65
4.4.2 CROSS-SECTOR OPPORTUNITIES 66
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 67
4.5.1 KEY MOVES & STRATEGIC FOCUS 67
5 INDUSTRY TRENDS 68
5.1 PORTER’S FIVE FORCES ANALYSIS 68
5.1.1 BARGAINING POWER OF SUPPLIERS 69
5.1.2 BARGAINING POWER OF BUYERS 69
5.1.3 THREAT OF NEW ENTRANTS 69
5.1.4 THREAT OF SUBSTITUTES 70
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.2 MACROECONOMIC INDICATORS 70
5.2.1 INTRODUCTION 70
5.2.2 GDP TRENDS & FORECAST 70
5.3 SUPPLY CHAIN ANALYSIS 74
5.4 VALUE CHAIN ANALYSIS 75
5.5 ECOSYSTEM ANALYSIS 77
5.6 PRICING ANALYSIS 78
5.6.1 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024–2026 78
5.6.2 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026 79
5.7 TRADE ANALYSIS 81
5.7.1 IMPORT SCENARIO (HS CODE 3822) 81
5.7.2 EXPORT SCENARIO (HS CODE 3822) 82
5.8 KEY CONFERENCES & EVENTS, 2026–2027 83
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 84
5.10 INVESTMENT & FUNDING SCENARIO 84
5.11 IMPACT OF 2025 US TARIFFS ON TRANSPLANT DIAGNOSTICS MARKET 85
5.11.1 INTRODUCTION 85
5.11.2 KEY TARIFF RATES 85
5.11.3 PRICE IMPACT ANALYSIS 86
5.11.4 IMPACT ON REGION 86
5.11.4.1 North America 87
5.11.4.2 Europe 87
5.11.4.3 Asia Pacific 87
5.11.5 IMPACT ON END-USE INDUSTRIES 88
5.11.5.1 Hospitals & transplant centers 88
5.11.5.2 Research & academic institutes 88
5.11.5.3 Independent reference laboratories 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 KEY EMERGING TECHNOLOGIES 89
6.1.1 DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) 89
6.1.2 DIGITAL PCR (DPCR) 89
6.2 COMPLEMENTARY TECHNOLOGIES 90
6.2.1 AI IN TRANSPLANT DIAGNOSTICS 90
6.2.2 BIOINFORMATICS 90
6.3 ADJACENT TECHNOLOGIES 91
6.3.1 LIQUID BIOPSY 91
6.3.2 DIGITAL PATHOLOGY 91
6.4 TECHNOLOGY/PRODUCT ROADMAP 92
6.5 PATENT ANALYSIS 94
6.5.1 LIST OF KEY PATENTS 95
6.6 FUTURE APPLICATIONS 96
6.7 IMPACT OF AI/GENERATIVE AI ON TRANSPLANT DIAGNOSTICS MARKET 97
6.7.1 INTRODUCTION 97
6.7.2 TOP USE CASES & MARKET POTENTIAL 98
6.7.3 KEY COMPANIES IMPLEMENTING AI 98
6.7.4 FUTURE OF AI 99
7 SUSTAINABILITY & REGULATORY LANDSCAPE 100
7.1 REGIONAL REGULATIONS & COMPLIANCE 100
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
7.2 SUSTAINABILITY INITIATIVES 102
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN TRANSPLANT DIAGNOSTICS 102
7.2.1.1 Eco-friendly initiatives 103
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 103
 
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 105
8.1 DECISION-MAKING PROCESS 105
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 105
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 105
8.2.2 BUYING CRITERIA 106
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 107
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 108
8.5 MARKET PROFITABILITY 110
8.5.1 REVENUE POTENTIAL 110
8.5.2 COST DYNAMICS 110
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 111
9 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES 112
9.1 INTRODUCTION 113
9.2 REAGENTS & CONSUMABLES 113
9.2.1 REAGENTS & CONSUMABLES TO BE LARGEST AND FASTEST-GROWING SEGMENT IN TRANSPLANT DIAGNOSTICS MARKET 113
9.3 INSTRUMENTS 116
9.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 116
9.4 SOFTWARE & SERVICES 119
9.4.1 GROWING AUTOMATION & DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO SUPPORT MARKET GROWTH 119
10 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 123
10.1 INTRODUCTION 124
10.2 MOLECULAR ASSAYS 124
10.2.1 PCR-BASED MOLECULAR ASSAYS 128
10.2.1.1 Real-time PCR 132
10.2.1.1.1 Smaller sample volume requirements compared to conventional PCR technologies to drive demand 132
10.2.1.2 Sequence-specific primer-PCR (SSP-PCR) 135
10.2.1.2.1 Growing public-private investments for research activities to support market growth 135
10.2.1.3 Sequence-specific oligonucleotide-PCR (SSO-PCR) 138
10.2.1.3.1 Wide adoption of technique in PCR-based molecular assays market to fuel growth 138
10.2.1.4 Other PCR-based molecular assays 141
10.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 144
10.2.2.1 Sanger sequencing 148
10.2.2.1.1 Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market 148
10.2.2.2 Next-generation sequencing (NGS) 151
10.2.2.2.1 Low turnaround time and high-throughput sequencing to drive adoption of NGS 151
10.2.2.3 Other sequencing-based molecular assays 154
10.3 NON-MOLECULAR ASSAYS 157
10.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED TECHNIQUES TO HAMPER GROWTH 157
11 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 161
11.1 INTRODUCTION 162
11.2 DIAGNOSTIC APPLICATIONS 162
11.2.1 PRE-TRANSPLANTATION DIAGNOSTICS 166
11.2.1.1 Infectious disease testing 169
11.2.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market 169
11.2.1.2 Histocompatibility testing 172
11.2.1.2.1 Technological advancements and growing R&D activities to propel market 172
11.2.1.3 Blood profiling 175
11.2.1.3.1 Growing availability of molecular assay products to support market growth 175
11.2.2 POST-TRANSPLANTATION DIAGNOSTICS 178
11.2.2.1 Greater risk of disorders and infections post-transplantation to make diagnostics necessary step 178
11.3 RESEARCH APPLICATIONS 181
11.3.1 GROWING FUNDING FOR RESEARCH TO DRIVE MARKET 181
12 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE 185
12.1 INTRODUCTION 186
12.2 SOLID ORGAN TRANSPLANTATION 186
12.2.1 KIDNEY TRANSPLANTATION 190
12.2.1.1 Rising prevalence of kidney diseases to drive market 190
12.2.2 LIVER TRANSPLANTATION 193
12.2.2.1 Growing patient population with chronic liver diseases and increasing procedural volume to drive market 193
12.2.3 LUNG TRANSPLANTATION 196
12.2.3.1 Rising prevalence of chronic lung diseases to drive market 196
12.2.4 HEART TRANSPLANTATION 199
12.2.4.1 Increasing prevalence of chronic cardiac diseases to propel market 199
12.2.5 PANCREAS TRANSPLANTATION 202
12.2.5.1 Procedural complexity and risk of surgical complications to restrain growth 202
12.2.6 OTHER SOLID ORGAN TRANSPLANTATION 205
12.3 STEM CELL TRANSPLANTATION 208
12.3.1 RISING PROCEDURAL VOLUME AND GROWING RESEARCH ACTIVITIES TO DRIVE MARKET 208
 
12.4 SOFT TISSUE TRANSPLANTATION 211
12.4.1 TECHNOLOGICAL ADVANCEMENTS AND RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET 211
12.5 BONE MARROW TRANSPLANTATION 214
12.5.1 DEARTH OF WELL-TRAINED SURGEONS TO PERFORM BONE MARROW TRANSPLANTATION TO HINDER GROWTH 214
13 TRANSPLANT DIAGNOSTICS MARKET, BY END USER 218
13.1 INTRODUCTION 219
13.2 INDEPENDENT REFERENCE LABORATORIES 219
13.2.1 RISING CONSOLIDATION OF DIAGNOSTIC LABORATORIES TO DRIVE MARKET 219
13.3 HOSPITALS & TRANSPLANT CENTERS 222
13.3.1 GROWING PURCHASING POWER OF HOSPITALS & TRANSPLANT CENTERS TO SUPPORT MARKET GROWTH 222
13.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 225
13.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS IN GENOMICS-BASED TRANSPLANT DIAGNOSTIC RESEARCH TO DRIVE MARKET 225
14 TRANSPLANT DIAGNOSTICS MARKET, BY REGION 230
14.1 INTRODUCTION 231
14.2 NORTH AMERICA 231
14.2.1 US 238
14.2.1.1 Growing organ transplantation activity to support market expansion 238
14.2.2 CANADA 243
14.2.2.1 Growing transplant programs to support market growth 243
14.3 EUROPE 248
14.3.1 GERMANY 254
14.3.1.1 Expanding donor registry network to fuel market growth 254
14.3.2 UK 259
14.3.2.1 Rising transplant demand to support market growth 259
14.3.3 FRANCE 264
14.3.3.1 Growing organ donation initiatives to drive growth 264
14.3.4 ITALY 269
14.3.4.1 Increasing organ donation rates to drive market growth 269
14.3.5 SPAIN 274
14.3.5.1 Strong organ donation system to support market growth 274
14.3.6 REST OF EUROPE 279
14.4 ASIA PACIFIC 284
14.4.1 CHINA 291
14.4.1.1 Expanding transplantation programs to drive market growth 291
14.4.2 JAPAN 296
14.4.2.1 Growing transplant waiting population to support market growth 296
 
14.4.3 INDIA 301
14.4.3.1 Rising transplant procedures to drive market growth 301
14.4.4 AUSTRALIA 306
14.4.4.1 Rising number of solid organ transplantation procedures to drive market 306
14.4.5 SOUTH KOREA 311
14.4.5.1 Large transplant waiting population to drive market growth 311
14.4.6 REST OF ASIA PACIFIC 316
14.5 LATIN AMERICA 321
14.5.1 BRAZIL 327
14.5.1.1 Expanding transplant programs to drive market growth 327
14.5.2 MEXICO 332
14.5.2.1 Growing medical tourism to support market growth 332
14.5.3 REST OF LATIN AMERICA 337
14.6 MIDDLE EAST & AFRICA 342
14.6.1 UAE 348
14.6.1.1 Expanding organ donation programs to drive market growth 348
14.6.2 SAUDI ARABIA 353
14.6.2.1 Strengthening transplantation capabilities to support market growth 353
14.6.3 REST OF MIDDLE EAST & AFRICA 358
14.6.4 US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET VOLUME 363
15 COMPETITIVE LANDSCAPE 364
15.1 INTRODUCTION 364
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 364
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET 364
15.3 REVENUE ANALYSIS, 2023–2025 366
15.4 MARKET SHARE ANALYSIS, 2025 366
15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 367
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 369
15.5.1 STARS 369
15.5.2 EMERGING LEADERS 369
15.5.3 PERVASIVE PLAYERS 369
15.5.4 PARTICIPANTS 369
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 371
15.5.5.1 Company footprint 371
15.5.5.2 Region footprint 371
15.5.5.3 Product & service footprint 372
15.5.5.4 Application footprint 372
15.5.5.5 End-user footprint 373
 
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 374
15.6.1 PROGRESSIVE COMPANIES 374
15.6.2 RESPONSIVE COMPANIES 374
15.6.3 DYNAMIC COMPANIES 374
15.6.4 STARTING BLOCKS 374
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 376
15.6.5.1 Detailed list of key startups/SMEs 376
15.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 376
15.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 377
15.7 COMPANY VALUATION & FINANCIAL METRICS 377
15.7.1 FINANCIAL METRICS 377
15.7.2 COMPANY VALUATION 378
15.8 BRAND/PRODUCT COMPARISON 378
15.9 COMPETITIVE SCENARIO 379
15.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 379
15.9.2 DEALS 381
15.9.3 EXPANSIONS 384
16 COMPANY PROFILES 386
16.1 KEY PLAYERS 386
16.1.1 THERMO FISHER SCIENTIFIC INC. 386
16.1.1.1 Business overview 386
16.1.1.2 Products offered 387
16.1.1.3 Recent developments 391
16.1.1.3.1 Product & service launches 391
16.1.1.3.2 Deals 391
16.1.1.3.3 Expansions 392
16.1.1.4 MnM view 393
16.1.1.4.1 Right to win 393
16.1.1.4.2 Strategic choices 393
16.1.1.4.3 Weaknesses & competitive threats 393
16.1.2 F. HOFFMANN-LA ROCHE LTD. 394
16.1.2.1 Business overview 394
16.1.2.2 Products offered 395
16.1.2.3 Recent developments 397
16.1.2.3.1 Product launches & approvals 397
16.1.2.3.2 Deals 398
16.1.2.4 MnM view 398
16.1.2.4.1 Right to win 398
16.1.2.4.2 Strategic choices 398
16.1.2.4.3 Weaknesses & competitive threats 398
 
16.1.3 BIO-RAD LABORATORIES, INC. 399
16.1.3.1 Business overview 399
16.1.3.2 Products offered 400
16.1.3.3 Recent developments 403
16.1.3.3.1 Product launches 403
16.1.3.3.2 Deals 403
16.1.3.4 MnM view 404
16.1.3.4.1 Right to win 404
16.1.3.4.2 Strategic choices 404
16.1.3.4.3 Weaknesses & competitive threats 404
16.1.4 QIAGEN N.V. 405
16.1.4.1 Business overview 405
16.1.4.2 Products offered 406
16.1.4.3 Recent developments 410
16.1.4.3.1 Product launches & approvals 410
16.1.4.3.2 Deals 410
16.1.4.4 MnM view 411
16.1.4.4.1 Right to win 411
16.1.4.4.2 Strategic choices 411
16.1.4.4.3 Weaknesses & competitive threats 411
16.1.5 BIOMÉRIEUX 412
16.1.5.1 Business overview 412
16.1.5.2 Products offered 413
16.1.5.3 Recent developments 415
16.1.5.3.1 Product launches & approvals 415
16.1.5.3.2 Deals 415
16.1.5.4 MnM view 416
16.1.5.4.1 Right to win 416
16.1.5.4.2 Strategic choices 416
16.1.5.4.3 Weaknesses & competitive threats 416
16.1.6 ILLUMINA, INC. 417
16.1.6.1 Business overview 417
16.1.6.2 Products offered 418
16.1.6.3 Recent developments 420
16.1.6.3.1 Deals 420
16.1.7 BECTON, DICKINSON AND COMPANY 421
16.1.7.1 Business overview 421
16.1.7.2 Products offered 422
16.1.7.3 Recent developments 423
16.1.7.3.1 Deals 423
 
16.1.8 CAREDX, INC. 424
16.1.8.1 Business overview 424
16.1.8.2 Products offered 425
16.1.8.3 Recent developments 427
16.1.8.3.1 Product launches 427
16.1.8.3.2 Deals 428
16.1.9 DIASORIN S.P.A. 429
16.1.9.1 Business overview 429
16.1.9.2 Products offered 430
16.1.9.3 Recent developments 431
16.1.9.3.1 Product launches 431
16.1.9.3.2 Deals 432
16.1.10 WERFEN 433
16.1.10.1 Business overview 433
16.1.10.2 Products offered 434
16.1.10.3 Recent developments 435
16.1.10.3.1 Product launches 435
16.1.10.3.2 Deals 435
16.1.11 MERCK KGAA 436
16.1.11.1 Business overview 436
16.1.11.2 Products offered 437
16.1.11.3 Recent developments 438
16.1.11.3.1 Deals 438
16.1.11.3.2 Expansions 438
16.1.12 HOLOGIC, INC. 440
16.1.12.1 Business overview 440
16.1.12.2 Products offered 441
16.2 OTHER PLAYERS 442
16.2.1 EUROBIO SCIENTIFIC 442
16.2.2 BIOFORTUNA LIMITED 443
16.2.3 BAG DIAGNOSTICS GMBH 444
16.2.4 FUJIREBIO 445
16.2.5 HISTOGENETICS LLC 446
16.2.6 PACBIO 447
16.2.7 TBG BIOTECHNOLOGY CORP 448
16.2.8 SCISCO GENETICS, INC. 449
16.2.9 INNO-TRAIN DIAGNOSTIK GMBH 450
16.2.10 BIONOBIS 451
16.2.11 TAKARA BIO INC. 451
16.2.12 KRISHGEN BIOSYSTEMS PRIVATE LIMITED 452
16.2.13 PROIMMUNE LTD. 452
17 RESEARCH METHODOLOGY 453
17.1 RESEARCH DATA 453
17.1.1 SECONDARY DATA 454
17.1.1.1 List of secondary sources 454
17.1.1.2 Key data from secondary sources 455
17.1.2 PRIMARY DATA 455
17.1.2.1 List of primary sources 456
17.1.2.2 Key data from primary sources 456
17.1.2.3 Key industry insights 457
17.1.2.4 Breakdown of primary interviews 458
17.2 MARKET SIZE ESTIMATION 458
17.2.1 TOTAL MARKET SIZE: TRANSPLANT DIAGNOSTICS MARKET 458
17.2.2 BOTTOM-UP APPROACH 458
17.2.2.1 Approach 1: Revenue estimation of key players 459
17.2.2.2 Approach 2: Study of annual reports and investor presentations 459
17.2.2.3 Approach 3: Primary interviews 459
17.2.2.4 Growth forecast 460
17.2.2.5 CAGR projections 460
17.2.3 TOP-DOWN APPROACH 461
17.3 DATA TRIANGULATION 462
17.4 RESEARCH ASSUMPTIONS 463
17.4.1 STUDY-RELATED ASSUMPTIONS 463
17.5 STUDY ASSUMPTIONS 463
17.5.1 PARAMETRIC ASSUMPTIONS 464
17.5.2 GROWTH RATE ASSUMPTIONS 464
17.6 RESEARCH LIMITATIONS 464
17.7 RISK ASSESSMENT 465
18 APPENDIX 466
18.1 DISCUSSION GUIDE 466
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 480
18.3 CUSTOMIZATION OPTIONS 482
18.4 RELATED REPORTS 482
18.5 AUTHOR DETAILS 483

ページTOPに戻る

List of Tables/Graphs

TABLE 1 TRANSPLANT DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 69
TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 71
TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 72
TABLE 4 EUROPE: MACROECONOMIC INDICATORS 72
TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS 73
TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS 73
TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 73
TABLE 8 TRANSPLANT DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 77
TABLE 9 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS,
BY KEY PLAYER, 2024–2026 (USD) 79
TABLE 10 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS,
BY REGION, 2024–2026 (USD) 80
TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 81
TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 82
TABLE 13 TRANSPLANT DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 83
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 85
TABLE 15 KEY PATENTS IN TRANSPLANT DIAGNOSTICS MARKET, 2022–2026 95
TABLE 16 KEY COMPANIES IMPLEMENTING AI IN TRANSPLANT DIAGNOSTICS MARKET 99
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE (%) 106
TABLE 23 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 106
TABLE 24 ADOPTION BARRIERS & INTERNAL CHALLENGES 107
TABLE 25 TRANSPLANT DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS
END-USE INDUSTRIES 109
TABLE 26 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 113
TABLE 27 TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES,
BY REGION, 2024–2031 (USD MILLION) 114
TABLE 28 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 29 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 30 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 31 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 32 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 33 TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2024–2031 (USD MILLION) 117
TABLE 34 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 35 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 36 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 37 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 38 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 39 TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 40 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 41 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 42 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 43 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 44 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 45 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 124
TABLE 46 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE,
2024–2031 (USD MILLION) 125
TABLE 47 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 48 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 49 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 50 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 51 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 52 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 53 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2024–2031 (USD MILLION) 129
TABLE 54 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY REGION, 2024–2031 (USD MILLION) 129
TABLE 55 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 56 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 57 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 58 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 59 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 60 TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 61 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 62 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 63 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 64 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 65 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 66 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR,
BY REGION, 2024–2031 (USD MILLION) 136
TABLE 67 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 68 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 69 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 70 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 71 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 72 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 73 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 74 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 75 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 76 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 77 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 78 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 79 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 80 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 81 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 82 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 83 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 84 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 145
TABLE 85 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 86 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 87 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 88 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 89 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 90 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 91 TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 92 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 93 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 94 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 95 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 96 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 97 TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY REGION, 2024–2031 (USD MILLION) 152
TABLE 98 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 99 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 100 ASIA PACIFIC: TRANSPLANT DIAGNOSTICSARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 101 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 102 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 103 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 104 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 105 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 106 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 107 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 108 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 109 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 158
TABLE 110 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 111 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 112 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 113 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 114 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR
NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 115 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 162
TABLE 116 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 117 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 163
TABLE 118 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 119 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 120 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 121 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 122 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 123 TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 166
TABLE 124 TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 167
TABLE 125 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 126 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 127 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 128 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 129 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 130 TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING,
BY REGION, 2024–2031 (USD MILLION) 170
TABLE 131 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 132 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 133 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 134 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 135 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 136 TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING,
BY REGION, 2024–2031 (USD MILLION) 173
TABLE 137 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 138 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 139 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 140 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 141 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 142 TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY REGION,
2024–2031 (USD MILLION) 176
TABLE 143 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING,
BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 144 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 145 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 146 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 147 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 148 TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 179
TABLE 149 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 150 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 151 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 152 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 153 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 154 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 182
TABLE 155 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 156 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 157 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 158 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 159 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 160 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 161 TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION,
BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 162 TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION,
BY REGION, 2024–2031 (USD MILLION) 187
TABLE 163 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 164 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 165 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 166 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 167 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 168 TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 191
TABLE 169 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 170 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION,
BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 171 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 172 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 173 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 174 TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 175 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 176 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION,
BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 177 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 178 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 179 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 180 TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 197
TABLE 181 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 182 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION,
BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 183 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 184 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 185 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 186 TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 200
TABLE 187 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 188 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION,
BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 189 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 190 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 191 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 192 TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION,
BY REGION, 2024–2031 (USD MILLION) 203
TABLE 193 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 194 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 195 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 196 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 197 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 198 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 199 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 200 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 201 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 202 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 203 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 204 TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION,
BY REGION, 2024–2031 (USD MILLION) 209
TABLE 205 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 206 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 207 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 208 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 209 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 210 TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION,
BY REGION, 2024–2031 (USD MILLION) 212
TABLE 211 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 212 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 213 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 214 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 215 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 216 TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION,
BY REGION, 2024–2031 (USD MILLION) 215
TABLE 217 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 218 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 219 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 220 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 221 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 222 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 219
TABLE 223 TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 220
TABLE 224 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 225 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 226 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 227 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 228 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 229 TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2024–2031 (USD MILLION) 223
TABLE 230 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 231 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 232 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 233 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 234 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 235 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 226
TABLE 236 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 237 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 238 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 239 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 240 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 241 TRANSPLANT DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 231
TABLE 242 NORTH AMERICA: MACROECONOMIC INDICATORS 232
TABLE 243 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 233
TABLE 244 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 233
TABLE 245 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 233
TABLE 246 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 247 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 248 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 249 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 235
TABLE 250 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 251 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR
PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 252 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 236
TABLE 253 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 254 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 237
TABLE 255 US: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 239
TABLE 256 US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 239
TABLE 257 US: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 258 US: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 259 US: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 260 US: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 241
TABLE 261 US: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 262 US: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 263 US: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 264 US: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 265 US: TRANSPLANT DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 243
TABLE 266 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 244
TABLE 267 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 244
TABLE 268 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 269 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 270 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 271 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 246
TABLE 272 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 273 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 274 CANADA: TRANSPLANT DIAGNOSTICS MARKET,